Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. Jacques Gardette

Market Cap

101.65 Million EUR

Sector

Healthcare

Website

https://biocorpsys.com

Description

Biocorp Production designs, develops, and manufactures medical devices and drug delivery systems in France.

Read More

Overview

Value

1

Growth

20

Health

39

Management

65

Analyst Opinion

94

Total

44

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Low risk of bankruptcy
  • Liked by analysts
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Income is not covering expenditure and investment
  • There is a history of diluting shareholders
  • Has a high level of debt
  • No margin of safety at their current market price
  • Poor earnings and cashflow growth
  • 0

Market Peers

ALCOR.PA

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-103.29%

Revenue Growth (5 Year Average)

N/A

Ratings Consensus

Strong Buy

Share Buybacks

-0.56%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

1

  • Estimated intrinsic-value of NaN undefined EUR is lower than current price ( 23.10 EUR)
  • Free-cashflow-yeild of -0.71% is worse than the market average (4.7%)
  • Margin-of-safety of -103.29% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 22.2 EUR

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-0.71%

PE/Earnings Growth

N/A

Price/Book

Infinityx

Growth

Growth Score

20

  • Revenue growth has improved this yeara
  • Earnings growth has improved this year
  • Free Cashflow growth has improved this year
  • 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
  • 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
  • 5 Year Average Free Cashflow growth of N/A is lower than the market average (12.35%)

Revenue Growth

N/A

Earnings Growth

N/A

Cashflow Growth

N/A

Health

Health Score

39

  • Low risk of bankruptcy
  • Assets cover liabilities
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • Has a high level of debt
  • Debt repayments significantly impact cashflow

Altman Z Score

7.90

Piostroski Score

5.00

Debt/Equity

131.70x

Current Assets/Liabilities

1.10x

Free Cashflow/Total Debt

0.05x

Debt/Capital

0.88x

Management

Management Score

65

  • Has issued new shares to finance growth when share price is high
  • Return-on-equity of 798.43% is higher than the market average (15%)
  • Return-on-capital-employed of 5.38% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity

Average Buybacks/Dilution

-0.56%

Recent Buybacks/Dilution

6.09%

5 Year Price Volitility

19.64%

Return On Assets

3.76%

Return On Capital Employed

5.38%

Return On Equity

798.43%

Return On Free Cashflow

110.82%

Return On Investments

66.99%

Analysts

Analyst Opinion

94

  • Ratings consensus is Strong Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Currency

EUR

Beta

Vol Avg

Ceo

Mr. Jacques Gardette

Cik

Cusip

F10197105

Exchange

Paris

Full Time Employees

Industry

Medical Devices

Sector

Healthcare

Ipo Date

Address

Parc Technologique

City

Issoire

State

Country

Zip

63500

Phone

33 4 73 55 70 50

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies